Literature DB >> 7536369

Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate.

K Akakura1, S Akimoto, T Ohki, J Shimazaki.   

Abstract

OBJECTIVES: A case report is presented of 2 patients whose levels of serum prostate-specific antigen (PSA) improved after the withdrawal of a steroidal antiandrogen.
METHODS: Two cases with prostate cancer had been treated with surgical castration and the steroidal antiandrogen chlormadinone acetate (CMA), and, on disease progression, the administration of CMA was terminated.
RESULTS: Following withdrawal of CMA, a fall in PSA levels and remarkable clinical improvement were observed in both cases. One patient revealed a decrease and the other an increase in serum prostate acid phosphatase after the discontinuation of CMA. Serum levels of testosterone, prolactin, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and androstenedione were not significantly elevated after CMA withdrawal.
CONCLUSIONS: Withdrawal of the steroidal antiandrogen CMA resulted in a decline in PSA levels and clinical improvement in prostate cancer patients with disease progression. Changes in testosterone, prolactin, or adrenal androgens were not a cause of the antiandrogen withdrawal syndrome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536369     DOI: 10.1016/S0090-4295(99)80070-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

Review 1.  Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

Authors:  David Lorente; Joaquin Mateo; Zafeiris Zafeiriou; Alan D Smith; Shahneen Sandhu; Roberta Ferraldeschi; Johann S de Bono
Journal:  Nat Rev Urol       Date:  2015-01       Impact factor: 14.432

2.  Delayed antiandrogen withdrawal syndrome after discontinuation of bicalutamide.

Authors:  Andrew J Cowan; Yoshio Inoue; Evan Y Yu
Journal:  Clin Genitourin Cancer       Date:  2014-09-22       Impact factor: 2.872

3.  Oral low-dose dexamethasone for androgen-independent prostate cancer patients.

Authors:  Akira Komiya; Masaki Shimbo; Hiroyoshi Suzuki; Takashi Imamoto; Tomonori Kato; Satoshi Fukasawa; Naoto Kamiya; Yukio Naya; Ikuo Mori; Tomohiko Ichikawa
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

Review 4.  Secondary hormonal manipulation of prostate cancer.

Authors:  K A Harris; E J Small
Journal:  Curr Urol Rep       Date:  2001-06       Impact factor: 3.092

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.